Two late-breaking abstracts covering new data from Inventiva’s NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of NASH have been selected for poster presentations during the ...
CAMBRIDGE, Mass., Nov. 13, 2020 /PRNewswire/ -- Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, today announced first-in-human clinical ...
Treatment modalities for patients with HCC. TACE: transarterial chemoembolization; SBRT: stereotactic body radiotherapy; OLT: orthotopic liver transplant; BSC: best supportive care. This is an ASCO ...
WALTHAM, Mass.--(BUSINESS WIRE)--Echosens, a high-technology company offering the FibroScan family of products, is proud to announce a strong clinical tradition with continued presence at the upcoming ...
BOSTON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced late-breaker ...
Correlation of serum PIVKA-II and AFP level with portal vein tumor thrombus and BCLC stage in newly diagnosed hepatocellular carcinoma patients. This is an ASCO Meeting Abstract from the 2020 ASCO ...
SAN FRANCISCO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic ...
BOSTON -- A mathematical model predicts that the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) -- formerly known as nonalcoholic fatty liver disease (NAFLD) -- will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results